CDH1 and acromegaly: The clinical relevance of E-Cadherin in the personalized medicine of acromegaly is also highlighted in the ACROFAST trial, which utilized the IHC expression of this marker, without the addition of SSTR2, to stratify patients into standard or personalized treatment arms.